Want to see CMMB full AI Analyst Report?
Top Page
Chemomab Therapeutics
(NASDAQ:CMMB)
Select Model
Select Model
Rating:54Neutral
Price Target:
$2.50
▲(49.70% Upside)
Action:Reiterated
Date:05/23/26
The score is held back primarily by weak financial performance (pre-revenue, persistent losses, and negative free cash flow implying ongoing financing risk). This is partially offset by constructive technical momentum (price above key moving averages with a positive MACD). Valuation support is limited due to negative earnings and no dividend.
Positive Factors
Clinical-stage asset & mechanism (CCL24)
Nebokitug’s Phase 2 SPRING biomarker and proteomic signals showing dose-dependent improvements and modulation of core fibrotic and immune pathways validate the CCL24 target biology. Durable scientific validation strengthens the clinical rationale, increases partner interest, and reduces program risk over the medium term.
Negative Factors
Pre-revenue with persistent cash burn
Chemomab remains pre-revenue with negative operating and free cash flow across years. Although cash burn improved in 2025, the company still depends on external capital. This persistent funding need raises dilution and execution risk if market access tightens over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage asset & mechanism (CCL24)
Nebokitug’s Phase 2 SPRING biomarker and proteomic signals showing dose-dependent improvements and modulation of core fibrotic and immune pathways validate the CCL24 target biology. Durable scientific validation strengthens the clinical rationale, increases partner interest, and reduces program risk over the medium term.
Read all positive factors
Chemomab Therapeutics (CMMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.34M
Dividend YieldN/A
Average Volume (3M)207.96K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue GrowthN/A
EPS Growth63.33%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$15.00Price Target Upside798.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Chemomab Therapeutics Business Overview & Revenue Model
Company Description
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclona...
How the Company Makes Money
null...
Chemomab Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -53.25K | -66.83K | -57.77K | -34.02K |
| EBITDA | -7.93M | -9.50M | -13.96M | -25.39M | -28.48M | -12.33M |
| Net Income | -7.46M | -8.99M | -13.95M | -24.22M | -27.65M | -12.48M |
Balance Sheet | ||||||
| Total Assets | 11.81M | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M |
| Cash, Cash Equivalents and Short-Term Investments | 8.04M | 10.37M | 14.27M | 19.78M | 39.89M | 61.16M |
| Total Debt | 0.00 | 0.00 | 324.00K | 392.00K | 214.00K | 343.00K |
| Total Liabilities | 1.11M | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M |
| Stockholders Equity | 10.70M | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M |
Cash Flow | ||||||
| Free Cash Flow | -11.22M | -11.22M | -15.46M | -23.55M | -20.36M | -12.62M |
| Operating Cash Flow | -11.22M | -11.22M | -15.46M | -23.55M | -20.29M | -12.38M |
| Investing Cash Flow | 5.43M | 5.43M | 2.31M | 15.84M | 19.46M | -45.22M |
| Financing Cash Flow | 7.21M | 7.21M | 9.91M | 3.49M | -804.84K | 61.12M |
Chemomab Therapeutics Technical Analysis
Positive
1.67
Price Trends
1.70
Positive
1.70
Positive
2.06
Positive
Market Momentum
0.02
Negative
74.30
Negative
73.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMMB, the sentiment is Positive. The current price of 1.67 is below the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.70, and below the 200-day MA of 2.06, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 74.30 is Negative, neither overbought nor oversold. The STOCH value of 73.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMMB.
Chemomab Therapeutics Risk Analysis
Chemomab Therapeutics disclosed 60 risk factors in its most recent earnings report. Chemomab Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chemomab Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $309.99M | 4.88 | 230.68% | ― | ― | ― | |
58 Neutral | $410.08M | -10.96 | -56.32% | ― | ― | 43.48% | |
54 Neutral | $16.34M | -2.06 | -89.92% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $15.25M | -0.73 | -526.36% | ― | ― | 16.33% | |
47 Neutral | $21.82M | -0.60 | -119.92% | ― | -45.35% | 58.32% | |
43 Neutral | $15.04M | -0.39 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
CMMB
Chemomab Therapeutics
2.27
-2.33
-50.65%
TENX
Tenax Therapeutics
15.46
9.71
168.87%
QTTB
Q32 Bio
13.09
11.73
862.50%
PASG
Passage Bio
4.68
-3.98
-45.96%
CALC
CalciMedica
0.97
-0.65
-40.06%
LGVN
Longeveron
0.69
-0.60
-46.51%
Chemomab Therapeutics Corporate Events
Chemomab Therapeutics Revamps Board and Committees With New Independent Director
Jun 2, 2026
On June 1, 2026, Chemomab Therapeutics’ board appointed veteran biotech dealmaker Gwen Melincoff as a Class I director and chair of the nominating and governance committee, expanding the board to five members and adding extensive business de...
Chemomab Highlights New Nebokitug Data in PSC as Q1 2026 Update Underscores PSC–IBD Potential
May 14, 2026
On May 14, 2026, Chemomab reported first-quarter 2026 results and a corporate update centered on new clinical and translational data for nebokitug in primary sclerosing cholangitis. The company highlighted recent and upcoming presentations at Dige...
Chemomab Shareholders Approve Governance Resolutions and Capital Increase at May 5 Meeting
May 6, 2026
On May 5, 2026, Chemomab Therapeutics held its adjourned annual general shareholders meeting in Ramat Gan, Israel, where investors approved key corporate governance items under Israeli law. Shareholders re-elected Class II directors Neil Cohen and...
Chemomab Adjourns April 28 Shareholder Meeting to May 5 After Quorum Shortfall
Apr 28, 2026
Chemomab Therapeutics announced that its Annual General Meeting of Shareholders, originally scheduled for April 28, 2026 in Ramat Gan, Israel, was adjourned due to a lack of quorum. The meeting has been rescheduled for May 5, 2026 at the same time...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.